Neoadjuvant Therapy for Men with High Risk Disease, Genomic Testing and Hereditary Prostate Cancer and Other Top Viewed Videos
Urology News and Education Resource
Sunday, 03 November 2024
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy
Mary-Ellen Taplin
Mary-Ellen Taplin, MD has a discussion with Dr. Alicia Morgans on the topic of neoadjuvant therapy for men with high risk disease prior to surgery, specifically, prior to prostatectomy.
Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer
Robert Hamilton
Dr. Robert Hamilton discusses Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer. He overviews clinical and biological rationale for radical prostatectomy in the oligometastases setting and highlights the role of novel imaging.
Prostate Cancer: Assorted Mortality Statistics
John Davis
John Davis from MD Anderson Cancer Center provides an overview of the prostate cancer mortality rate by referencing statistics from a unique database titled, Premier Perspective Database.
Genomic Testing and Hereditary Prostate Cancer- Interview with Leonard Gomella
Leonard Gomella
Leonard Gomella, MD gives Charles Ryan, MD an overview on the current state of the rapidly evolving field of genetic and genomic testing for prostate cancer.
Bone Metastases and Mortality: Can We Be Doing More?
Leonard Gomella, MD overviews the efforts and accomplishments thus far in bone metastases and mortality for prostate cancer and reflects on what else the field can be doing.
Discussion on FALCON: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer
Thomas Keane
Dr. Thomas Keane provides a commentary on the The FALCON Trial, the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.
Discussion on SPARTAN: A Study of Apalutamide in Men with Non-Metastatic Castration-resistant Prostate Cancer
Dr. Thomas Keane reviews recent groundbreaking data presented at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium focusing on the much awaited results of the SPARTAN trial.
You are receiving this email because you have chosen to receive emails from UroToday...
